SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
NCT ID: NCT00997061
Last Updated: 2014-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2009-11-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.
Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
NCT03425825
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
NCT06075615
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer
NCT00276276
Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer
NCT00006082
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
NCT01901653
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HYCAMTIN
HYCAMTIN
Observing patients on HYCAMTIN and other drugs for SCLC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HYCAMTIN
Observing patients on HYCAMTIN and other drugs for SCLC.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of small cell lung cancer
* Patient newly diagnosed with SCLC
* Has given written informed consent (if applicable)
Exclusion Criteria
* Patient presenting with recurrence of SCLC.
* Patients who has received any chemotherapy for the SCLC.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Graz, , Austria
GSK Investigational Site
Innsbruck, , Austria
GSK Investigational Site
Salzburg, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Pilsen, , Czechia
GSK Investigational Site
Tallinn, , Estonia
GSK Investigational Site
Besançon, , France
GSK Investigational Site
Caen, , France
GSK Investigational Site
Créteil, , France
GSK Investigational Site
Draguignan, , France
GSK Investigational Site
Lorient, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Perpignan, , France
GSK Investigational Site
Pessac, , France
GSK Investigational Site
Pierre-Bénite, , France
GSK Investigational Site
Saint-Priest-en-Jarez, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Immenhausen, Hesse, Germany
GSK Investigational Site
Kassel, Hesse, Germany
GSK Investigational Site
Wiesbaden, Hesse, Germany
GSK Investigational Site
Leer, Lower Saxony, Germany
GSK Investigational Site
Bonn, North Rhine-Westphalia, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Hemer, North Rhine-Westphalia, Germany
GSK Investigational Site
Velbert, North Rhine-Westphalia, Germany
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Heraklion, Crete, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Mátraháza, , Hungary
GSK Investigational Site
Székesfehérvár, , Hungary
GSK Investigational Site
Lecce, Apulia, Italy
GSK Investigational Site
Parma, Emilia-Romagna, Italy
GSK Investigational Site
Rozzano (MI), Lombardy, Italy
GSK Investigational Site
Orbassano (TO), Piedmont, Italy
GSK Investigational Site
Sassari, Sardinia, Italy
GSK Investigational Site
Kaunas, , Lithuania
GSK Investigational Site
Klaipėda, , Lithuania
GSK Investigational Site
Vilnius, , Lithuania
GSK Investigational Site
Vilnius, , Lithuania
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Breda, , Netherlands
GSK Investigational Site
Eindhoven, , Netherlands
GSK Investigational Site
Groningen, , Netherlands
GSK Investigational Site
Gorzów Wielkopolski, , Poland
GSK Investigational Site
Głuchołazy, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Lublin, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Golnik, , Slovenia
GSK Investigational Site
Ljubljana, , Slovenia
GSK Investigational Site
Seongnam-si, Gyeonggi-do, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Suwon, Gyeonggi-do, , South Korea
GSK Investigational Site
Córdoba, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Palma de Mallorca, , Spain
GSK Investigational Site
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
112791
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.